5-alpha reductase inhibitors (5-ARi) with or without alpha-blockers (α-B) for Benign Prostatic Hyperplasia do NOT lower the risk of incident Bladder Cancer: United States insurance claims data
Francesco Del Giudice(Sapienza University of Rome), Michael L. Eisenberg(Palo Alto University), Francesco Soria(Medical University of Vienna), Wojciech Krajewski(Wroclaw Medical University), Benjamin Pradère, Federico Belladelli(IRCCS Ospedale San Raffaele), Frank Glover(Emory University Hospital), Rajesh Nair(St Thomas' Hospital), Nicolas Seranio(Stanford University), Wade Muncey(Idaho Urologic Institute), Shufeng Li(Stanford University), Satvir Basran(Stanford Medicine), Evan Mulloy(Stanford University)
Cited by 12
Related Papers
Male Reproductive Disorders and Fertility Trends: Influences of Environment and Genetic Susceptibility
|Physiological Reviews|2015|938
Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC)
|World Journal of Urology|2016|471
The relationship between male BMI and waist circumference on semen quality: data from the LIFE study
|Human Reproduction|2013|338
Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and Its Clinical Impact on the Management of High-risk Non–muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection
|European Urology|2019|212
Semen quality and time to pregnancy: the Longitudinal Investigation of Fertility and the Environment Study
|Fertility and Sterility|2013|191